The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Adaptimmune; Blueprint Medicines; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immune Design; Lilly; Merck; PharmaMar; TRACON Pharma; UpToDate
Research Funding - MSD
Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma.
 
Mrinal M. Gounder
Honoraria - Bayer; Flatiron Health; Medscape; PER
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Springworks Therapeutics
Speakers' Bureau - Amgen
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Foundation Medicine
 
Silvia Stacchiotti
Honoraria - Lilly; PharmaMar; Takeda
Consulting or Advisory Role - Bavarian Nordic; Bayer; Daiichi Sankyo; Deciphera; Epizyme; Immune Design; Lilly; MaxiVax; PharmaMar
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines; Daiichi Sankyo (Inst); Epizyme (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Patrick Schoffski
Honoraria - Blueprint Medicines; Boehringer Ingelheim; Deciphera
Consulting or Advisory Role - Adaptimmune (Inst); Blueprint Medicines (Inst); Deciphera; Deciphera (Inst); Eisai (Inst); Ellipses Pharma (Inst); Exelixis (Inst); Genmab (Inst); Intellisphere (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Plexxikon (Inst); SERVIER (Inst); Transgene (Inst)
Research Funding - CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst); MSD (Inst)
 
Gregory Michael Cote
Consulting or Advisory Role - Agios; Epizyme; PharmaMar
Research Funding - Agios (Inst); Bavarian Nordic; Bayer (Inst); Boston Biomedical (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Plexxikon (Inst); Springworks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Victor Manuel Villalobos
Consulting or Advisory Role - Abbvie; Agios; Blueprint Medicines; Daiichi Sankyo; Epizyme; Ignyta; Janssen; Lilly; NanoCarrier; Novartis; Springworks Therapeutics
Travel, Accommodations, Expenses - Epizyme; GenMab; Janssen; Lilly; Xencor
 
Thierry Marie Jahan
Research Funding - Aduro Biotech; AstraZeneca; Bristol-Myers Squibb; Epizyme; Lilly; Polaris; Trizell
(OPTIONAL) Uncompensated Relationships - Atara Biotherapeutics
 
Tom Wei-Wu Chen
Honoraria - Daiichi Sankyo; Eisai; Lilly; Novartis; Roche
Consulting or Advisory Role - Blueprint Medicines; Daiichi Sankyo; Eisai
Research Funding - Eisai; Epizyme
Travel, Accommodations, Expenses - Eisai; Roche
 
Ravin Ratan
Consulting or Advisory Role - Epizyme
Other Relationship - Epizyme
 
Abha A. Gupta
No Relationships to Disclose
 
Palma Dileo
No Relationships to Disclose
 
Mark Agulnik
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Lilly; Regeneron
Speakers' Bureau - Bayer; Bristol-Myers Squibb
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Immune Design
 
Olivier Mir
Stock and Other Ownership Interests - Amplitude Surgical; Ipsen; Transgene
Honoraria - Roche
Consulting or Advisory Role - Janssen; Lilly; Lundbeck; Pfizer; Roche
Speakers' Bureau - Lilly; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Joseph Gerald Pressey
Honoraria - CSRA
Consulting or Advisory Role - Cellectar
 
Laura Sierra
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Trupti Lingaraj
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Jay Yang
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Shefali Agarwal
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
 
Robin L. Jones
No Relationships to Disclose